Guadecitabine, in combination with Cyclophosphamide, promotes anti-cancer immunity in BALB/c mice bearing 4T1 mouse mammary carcinoma

Carmen Camarena  
*Virginia Commonwealth University*

Timothy M. Smith  
Rebecca K. Martin PhD  
Harry D. Bear MD

Follow this and additional works at: [https://scholarscompass.vcu.edu/gradposters](https://scholarscompass.vcu.edu/gradposters)

Part of the Medicine and Health Sciences Commons

Downloaded from
Camarena, Carmen; Smith, Timothy M.; Martin PhD, Rebecca K.; and Bear MD, Harry D., "Guadecitabine, in combination with Cyclophosphamide, promotes anti-cancer immunity in BALB/c mice bearing 4T1 mouse mammary carcinoma" (2020). *Graduate Research Posters.* Poster 62.  
[https://scholarscompass.vcu.edu/gradposters/62](https://scholarscompass.vcu.edu/gradposters/62)

This Poster is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Graduate Research Posters by an authorized administrator of VCU Scholars Compass. For more information, please contact [libcompass@vcu.edu](mailto:libcompass@vcu.edu).
Guadecitabine, in combination with Cyclophosphamide, promotes anti-cancer immunity in BALB/c mice bearing 4T1 mouse mammary carcinoma

Carmen Camarena\textsuperscript{1,2}, Timothy M. Smith Jr.\textsuperscript{1,2}, Harry D. Bear\textsuperscript{1,2,3}, Rebecca K. Martin\textsuperscript{1,2}

\textsuperscript{1}VCU Department of Microbiology and Immunology, \textsuperscript{2}Massey Cancer Center, \textsuperscript{3}Department of Surgery

Abstract

Since 1990, death rates in females from breast cancer have been in decline (from \textasciitilde33 deaths per 100,000 population in 1990 to \textasciitilde20 deaths per 100,000 population in 2016). Many breast cancers are treated with therapies that target Herceptin, estrogen, or progesterone receptors; however, for triple-negative breast cancers (TNBC) that lack these receptors, treatment options are limited and prognosis is often unfavorable. The goal of this study is to design a therapeutic intervention that is able to elicit an effective immune response against the tumor and instill immunological memory to eradicate primary and metastatic lesions. Guadecitabine (Guad) is a second-generation DNA methyltransferase inhibitor (DMNITI) that has been reported to have several antitumor properties such as increased antigenicity and depletion of myeloid-derived suppressor cells (MDSC’s). Cyclophosphamide is a FDA approved chemotherapy that has been shown, when given as a low-dose treatment, to selectively deplete regulatory T-cells (T-regs). Both MDSCs and T-regs suppress antitumor immunity. We hypothesize that the combination of Guad and Cyp will synergize and promote antitumor immunity through increased expression of de novo tumor antigens and depletion of MDSCs and T-regs in a low-dose setting. To test this hypothesis, BALB/c mice were challenged with murine TNBC 4T1 tumor cells and the 4T1-bearing mice were administered low-dose Guad and Cyp daily for ten consecutive days. This experiment showed a degree of synergy between Guad and Cyp with the dual therapy reducing tumor burden to a greater extent than either monotherapy.

Methods

Results

Figure 1. Dual treatment of low-dose guadecitabine with low-dose cyclophosphamide results in decreased tumor burden. Mice were challenged with 4T1 cells and received either vehicle control, low-dose guadecitabine, low-dose cyclophosphamide, or a combination of both therapies. A) Tumor volumes were measured using digital calipers every 3-4 days following tumor challenge. B) On Day 19, mice were euthanized and spleen weight was taken. Error bars depict SEM.

Figure 2. Reduction in the percent of splenic T- regulatory cells in mice receiving both low-dose guadecitabine and cyclophosphamide. Flow cytometry was performed on splenocytes from mice harvested in Fig. 1b to analyse the T-cell compartment. T-cells were defined as live cells that were also TCRβ+; CD4, CD8, and T regulatory cells were defined as T cells that expressed CD4, CD8, or FoxP3 respectively. The graphs represent the percent of each type of T-cell of total live T cells. Error bars depict SEM.

Figure 3. Treatment with low-dose guadecitabine and cyclophosphamide skews splenic T-cells towards an effector/effector-memory phenotype. Flow cytometry was performed on splenocytes from mice harvested in Fig. 1b to analyse the T-cell compartment. T-cells were defined as live cells that were also TCRβ+. Naïve cells were CD44-, Effector cells were CD44+, and Memory cells were CD44+CD62L+. A) Graphs show the naïve, effector, or memory CD4+ T cell population as a percent of total live CD4+ cells. B) Graphs show the naïve, effector, or memory CD8+ T cell population as a percent of total live CD8+ cells. Error bars depict SEM.

Figure 4. Low-dose guadecitabine depletes splenic MDSCs. Flow cytometry was performed on splenocytes from mice harvested in Fig. 1b to analyse the myeloid compartment. MDSCs were defined as live cells that were also CD11b+ and either Ly6G+ or Ly6C+. A) MDSCs were defined as live cells that were also CD11b+ and either Ly6G+ or Ly6C+. B) MDSCs were defined as live CD11b+Ly6G+ or Ly6C+. C) Monocytic MDSCs were defined as live CD11b+Ly6C+ and D) granulocytic MDSCs were defined as live CD11b+Ly6G+. Error bars depict SEM.

Conclusions/Future Direction

Our findings support our hypothesis that combinational therapy with both Guadecitabine and Cyclophosphamide induce an antitumor environment and reduce tumor burden more effectively than either treatment alone. To further solidify our hypothesis, other experimental designs may be beneficial to execute including but not limited to:

- Extending the experiment to produce a survival analysis
- Including counting beads to have cell counts and not only percent
- Conduct the same experiment using C57BL/6 mice model in vivo
- Design and execute an in vitro study using same experimental parameters

Acknowledgements

This work was supported by NIH/NIAID grant numbers R01AI18697A1 and R01AI139658 to (R. Martin). Services and products in support of the research project were generated by the VCU Massey Cancer Center Flow Cytometry Shared Resource, supported, in part, with funding from NIH/NIH Cancer Center Support Grant P30 CA043490. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the NIH/NIAID. I would also like to acknowledge Astex Pharmaceuticals, Inc. for kindly providing Guadecitabine. In addition, I would like to thank members of the Martin Lab and Bear Lab for all the assistance they provided.